We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aspen Pharma and Deco Pharma, the company’s distributor, face disciplinary proceedings from Spain’s antitrust authority for allegedly limiting the distribution and hiking the prices of drugs. Read More
A lawsuit filed by the state of California alleges several drug manufacturers made a “pay-for-delay” deal to keep generic competition off the market. Read More
Former FDA deputy commissioner Scott Gottlieb emerged as the favorite to serve as the next leader of the FDA in a survey of 53 pharmaceutical companies. Read More
The EMA is clarifying agency expectations on the implementation of risk-based models and exposure limits to prevent cross-contamination during manufacturing in a Q&A guideline, telling manufacturers that all products should have health-based exposure limits (HBEL). Read More
Unrestricted access to electronic records and a series of quality control deficiencies resulted in a seven-observation 483 for a specialty drugmaker based in Maryland. Read More
The FTC is asking a Georgia federal court to remove Par Pharmaceuticals and Paddock Laboratories from an antitrust case that alleges the companies delayed the market entry of their AndroGel generics in exchange for payments. Read More
The federal government issued a subpoena to Biogen requesting information on prices, rebates and co-assistance programs for four of its therapies, according to an SEC filing by the company. Read More